Bridge to Life Secures $110 Million for Organ Transplant Innovation. VitaSmart Drives Commercial Surge.
August 25, 2026, 9:38 am
Bridge to Life secured $110 million in Series C equity and debt financing. This significant capital influx will accelerate the nationwide commercialization of VitaSmart, its FDA-cleared hypothermic oxygenated perfusion system for liver transplantation. Funds also fuel a broader pipeline of organ preservation and viability assessment technologies. The company aims to expand its reach to every U.S. transplant center, addressing critical organ shortages. VitaSmart, the first and only FDA-authorized HOPE system for livers, enhances donor organ utilization. This financing solidifies Bridge to Life's transition from development to a leading commercial entity, poised to revolutionize transplant medicine and save countless lives through innovative organ care solutions.
Bridge to Life commands attention. The organ preservation leader announced a substantial financial coup. It closed $110 million in Series C equity and debt financing. This capital infusion will redefine organ transplant care. New investor Soleus Capital led the equity round. Lauxera Capital Partners joined. Bridge to Life directors, officers, and employees also participated. Soleus Capital Credit Opportunities Fund provided the debt financing.
This funding is transformative. It immediately bolstered the company’s financial standing. Bridge to Life refinanced its existing credit facility. Perceptive Credit Funds previously held this. The refinancing significantly reduced outstanding leverage. It also lowered interest rates. Bridge to Life stands on stronger financial ground. It transitions from an early-stage developer. It is now a fully commercial organization.
The primary target for this investment is VitaSmart. This hypothermic oxygenated perfusion (HOPE) system is revolutionary. It received U.S. Food and Drug Administration (FDA) De Novo clearance. This occurred in January 2026. VitaSmart holds a unique position. It is the first and only FDA-authorized HOPE system. Its use is specifically for liver transplantation.
VitaSmart supports donor livers. It does so through hypothermic oxygenated perfusion. This process occurs before transplantation. The system optimizes liver viability. It extends the window for successful transplantation. This innovation is critical. It addresses a profound medical need.
Initial commercial rollout of VitaSmart exceeded expectations. U.S. transplant centers adopted it rapidly. Academic transplant centers are utilizing the system. Organ procurement organizations (OPOs) also embrace it. Several high-volume liver transplant programs are now users. Repeat orders demonstrate market confidence. An additional pipeline of U.S. centers moves towards adoption. The demand for advanced organ preservation technology is clear.
The context is stark. Over 100,000 patients in the U.S. await life-saving organ transplants. Many donor organs go unused. This wastage often stems from viability concerns. Traditional cold static preservation has limits. Perfusion technologies offer a powerful solution. They can help transplant teams. They increase utilization of donor organs. These organs might otherwise be discarded. Bridge to Life positions VitaSmart directly against this challenge. It aims to save more lives.
Beyond VitaSmart, Bridge to Life nurtures a robust pipeline. A proprietary organ viability assessment tool is under development. This tool will provide objective information. It aids transplant teams in critical decisions. Deciding whether to accept an organ is complex. Current assessments rely on donor characteristics. Visual inspection plays a role. Clinical judgment is key. During normothermic perfusion, measures like lactate clearance and bile production are considered.
The investigational tool offers more. It adds a validated biomarker-based assessment. This provides additional decision support. It is crucial for marginal and extended-criteria organs. Such organs are often overlooked. The new tool could unlock their potential. It could expand the donor pool further. This viability assessment technology is still developing. It has not received clearance for commercial sale.
Bridge to Life plans further expansion. Its preservation and perfusion platform will grow. It will extend beyond liver transplantation. Additional solid-organ applications are targeted. This expansion will occur over the next three years. The company is also developing next-generation closed systems. These systems simplify organ transport. They support the growth of international operations.
VitaSmart complements an established franchise. Bridge to Life’s Belzer UW preservation solution is well-known. Belzer UW is used for cold static preservation. It supports abdominal organ transplantation. This comprehensive portfolio makes Bridge to Life a powerhouse. It offers varied solutions for diverse transplant needs.
The proceeds from the financing are strategic. They will expand VitaSmart’s commercial and clinical field teams. This expansion ensures widespread adoption. Working capital will reach every U.S. transplant center. This nationwide reach is paramount. It guarantees access to life-saving technology. Funds also propel the new product pipeline forward. Broadening the organ preservation portfolio is a key goal. Scaling global operations ensures wider impact.
This investment underscores a profound shift. Bridge to Life evolved. It moved from early development. It became a fully commercial organization. Its technology, team, and growth strategy instill confidence. Investors recognize the potential. They see a leader in transplant innovation. UBS Investment Bank served as financial advisor. Morgan, Lewis & Bockius provided legal counsel.
The medical landscape is changing. Organ transplantation faces persistent challenges. Bridge to Life offers tangible solutions. Its advanced medical technology improves outcomes. It expands organ availability. This benefits patients awaiting transplants. It strengthens the entire healthcare system.
Bridge to Life is committed. It seeks to improve transplant medicine. It does so through science-based solutions. These solutions bring more organs to more patients. The financing marks a critical milestone. It validates Bridge to Life’s vision. The future of organ care looks brighter. Innovation drives progress. Bridge to Life leads the charge. It helps fulfill the promise of life. It does this one organ at a time.
Bridge to Life commands attention. The organ preservation leader announced a substantial financial coup. It closed $110 million in Series C equity and debt financing. This capital infusion will redefine organ transplant care. New investor Soleus Capital led the equity round. Lauxera Capital Partners joined. Bridge to Life directors, officers, and employees also participated. Soleus Capital Credit Opportunities Fund provided the debt financing.
This funding is transformative. It immediately bolstered the company’s financial standing. Bridge to Life refinanced its existing credit facility. Perceptive Credit Funds previously held this. The refinancing significantly reduced outstanding leverage. It also lowered interest rates. Bridge to Life stands on stronger financial ground. It transitions from an early-stage developer. It is now a fully commercial organization.
The primary target for this investment is VitaSmart. This hypothermic oxygenated perfusion (HOPE) system is revolutionary. It received U.S. Food and Drug Administration (FDA) De Novo clearance. This occurred in January 2026. VitaSmart holds a unique position. It is the first and only FDA-authorized HOPE system. Its use is specifically for liver transplantation.
VitaSmart supports donor livers. It does so through hypothermic oxygenated perfusion. This process occurs before transplantation. The system optimizes liver viability. It extends the window for successful transplantation. This innovation is critical. It addresses a profound medical need.
Initial commercial rollout of VitaSmart exceeded expectations. U.S. transplant centers adopted it rapidly. Academic transplant centers are utilizing the system. Organ procurement organizations (OPOs) also embrace it. Several high-volume liver transplant programs are now users. Repeat orders demonstrate market confidence. An additional pipeline of U.S. centers moves towards adoption. The demand for advanced organ preservation technology is clear.
The context is stark. Over 100,000 patients in the U.S. await life-saving organ transplants. Many donor organs go unused. This wastage often stems from viability concerns. Traditional cold static preservation has limits. Perfusion technologies offer a powerful solution. They can help transplant teams. They increase utilization of donor organs. These organs might otherwise be discarded. Bridge to Life positions VitaSmart directly against this challenge. It aims to save more lives.
Beyond VitaSmart, Bridge to Life nurtures a robust pipeline. A proprietary organ viability assessment tool is under development. This tool will provide objective information. It aids transplant teams in critical decisions. Deciding whether to accept an organ is complex. Current assessments rely on donor characteristics. Visual inspection plays a role. Clinical judgment is key. During normothermic perfusion, measures like lactate clearance and bile production are considered.
The investigational tool offers more. It adds a validated biomarker-based assessment. This provides additional decision support. It is crucial for marginal and extended-criteria organs. Such organs are often overlooked. The new tool could unlock their potential. It could expand the donor pool further. This viability assessment technology is still developing. It has not received clearance for commercial sale.
Bridge to Life plans further expansion. Its preservation and perfusion platform will grow. It will extend beyond liver transplantation. Additional solid-organ applications are targeted. This expansion will occur over the next three years. The company is also developing next-generation closed systems. These systems simplify organ transport. They support the growth of international operations.
VitaSmart complements an established franchise. Bridge to Life’s Belzer UW preservation solution is well-known. Belzer UW is used for cold static preservation. It supports abdominal organ transplantation. This comprehensive portfolio makes Bridge to Life a powerhouse. It offers varied solutions for diverse transplant needs.
The proceeds from the financing are strategic. They will expand VitaSmart’s commercial and clinical field teams. This expansion ensures widespread adoption. Working capital will reach every U.S. transplant center. This nationwide reach is paramount. It guarantees access to life-saving technology. Funds also propel the new product pipeline forward. Broadening the organ preservation portfolio is a key goal. Scaling global operations ensures wider impact.
This investment underscores a profound shift. Bridge to Life evolved. It moved from early development. It became a fully commercial organization. Its technology, team, and growth strategy instill confidence. Investors recognize the potential. They see a leader in transplant innovation. UBS Investment Bank served as financial advisor. Morgan, Lewis & Bockius provided legal counsel.
The medical landscape is changing. Organ transplantation faces persistent challenges. Bridge to Life offers tangible solutions. Its advanced medical technology improves outcomes. It expands organ availability. This benefits patients awaiting transplants. It strengthens the entire healthcare system.
Bridge to Life is committed. It seeks to improve transplant medicine. It does so through science-based solutions. These solutions bring more organs to more patients. The financing marks a critical milestone. It validates Bridge to Life’s vision. The future of organ care looks brighter. Innovation drives progress. Bridge to Life leads the charge. It helps fulfill the promise of life. It does this one organ at a time.